## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.42 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($175.45)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Korea Investment CORP Purchases 12,300 Shares of Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251204T090928 | Bullish | Relevance: 100%
- Korea Investment CORP increased its stake in Quest Diagnostics (NYSE:DGX) by 37.9%, acquiring an additional 12,300 shares, bringing its total holdings to 44,729 shares valued at approximately $8.04 million. Despite insider selling, institutional investors now own about 88.06% of the company's stock. Quest Diagnostics recently surpassed quarterly earnings estimates, reported a 13.2% year-over-year revenue increase, and maintains a "Moderate Buy" consensus rating with a target price of $196.31.

**2. Distillate Capital Partners LLC Sells 4,577 Shares of Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251203T050820 | Somewhat-Bullish | Relevance: 100%
- Distillate Capital Partners LLC reduced its stake in Quest Diagnostics by 4.7%, selling 4,577 shares and bringing their total holdings to 93,774 shares valued at approximately $16.85 million. Despite the sale, analysts maintain a "Moderate Buy" rating for Quest Diagnostics with a consensus target price of $196.31, following strong quarterly earnings and increased price targets from several firms. The CEO also sold a significant number of shares, while the company announced a quarterly dividend of $0.80.

**3. New York State Common Retirement Fund Sells 7,619 Shares of Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251205T115732 | Neutral | Relevance: 100%
- The New York State Common Retirement Fund has reduced its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 12.6%, selling 7,619 shares and holding 53,063 shares valued at $9.53 million. This comes as other institutional investors have modified their positions, with insider selling also reported. Analysts currently rate Quest Diagnostics as a "Moderate Buy" with an average target price of $196.31.

**4. Looking Into Quest Diagnostics Inc's Recent Short Interest**
- Source: Benzinga | 20251204T130851 | Somewhat-Bearish | Relevance: 100%
- Quest Diagnostics Inc. (NYSE: DGX) has seen a 16.75% increase in its short interest, with 4.61 million shares now sold short, representing 4.74% of its float. This level of short interest indicates it would take traders 3.49 days to cover their positions. Despite the rise, Quest Diagnostics Inc.'s short interest is lower than its peer group average of 9.92%, suggesting less bearish sentiment compared to similar companies.

**5. 1,325,624 Shares in Quest Diagnostics Incorporated $DGX Purchased by Norges Bank**
- Source: MarketBeat | 20251203T150859 | Somewhat-Bullish | Relevance: 100%
- Norges Bank recently acquired a new position of 1,325,624 shares in Quest Diagnostics (NYSE:DGX), valued at approximately $238.1 million, representing about 1.19% ownership. This comes as Quest Diagnostics exceeded quarterly earnings estimates and provided a positive FY2025 guidance, contributing to a "Moderate Buy" consensus rating among analysts. Despite some insider selling, institutional investors collectively own 88.06% of the company's stock, reflecting strong confidence in the medical research firm.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 5 ($3.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.5M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.42 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.42 |
| Forward P/E | 17.6 |
| Current P/E | 18.6 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.9% to -4.3% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.77), momentum weakening. RSI neutral at 45. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.33% (CS: 15) | Weak |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.77 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.032x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $182.51
- **Stop Loss:** $175.45 (3.9% risk)
- **Target:** $196.63 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 70
- **Position Value:** $12,775.70
- **Portfolio %:** 12.78%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*